Duopharma Biotech Berhad has established PT Duopharma Healthcare Indonesia ("PT DHI") as a wholly-owned subsidiary of the company in the Republic of Indonesia. Confirmation of the approval of the establishment of PT DHI by the Ministry of Law and Human Rights of the Republic of Indonesia was received by the company on 11 April 2023. PT DHI is a limited liability company, with a current authorised and issued capital of IDR 10,001,000,000 comprising 10,001 shares.

Duopharma Consumer Healthcare Sdn Bhd (a wholly-owned subsidiary of Duopharma Biotech) holds 99% of shares while the remaining 1% is held directly by Duopharma Biotech.